Embecta Corp. (NASDAQ:EMBC) Short Interest Up 19.4% in March

Embecta Corp. (NASDAQ:EMBC) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 5,617,135 shares, an increase of 19.4% from the February 26th total of 4,703,024 shares. Currently, 9.6% of the company’s stock are short sold. Based on an average trading volume of 859,291 shares, the days-to-cover ratio is presently 6.5 days.

Embecta Trading Up 0.0%

Shares of Embecta stock traded up $0.00 during trading on Wednesday, reaching $8.84. The company’s stock had a trading volume of 674,785 shares, compared to its average volume of 827,242. The company has a 50-day moving average price of $9.93 and a two-hundred day moving average price of $12.06. Embecta has a fifty-two week low of $8.47 and a fifty-two week high of $15.55. The firm has a market cap of $523.56 million, a PE ratio of 3.73 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The firm had revenue of $261.20 million during the quarter, compared to analysts’ expectations of $258.07 million. During the same quarter in the prior year, the business earned $0.65 EPS. Embecta’s quarterly revenue was down .3% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. On average, analysts predict that Embecta will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 17th. Shareholders of record on Friday, February 27th were issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend was Friday, February 27th. Embecta’s payout ratio is currently 25.32%.

Institutional Trading of Embecta

Several hedge funds have recently modified their holdings of the business. Larson Financial Group LLC grew its holdings in Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after acquiring an additional 1,574 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares during the period. Wexford Capital LP purchased a new stake in shares of Embecta during the 3rd quarter worth $94,000. Humankind Investments LLC acquired a new position in shares of Embecta during the 2nd quarter worth $111,000. Finally, iSAM Funds UK Ltd acquired a new position in shares of Embecta during the 3rd quarter worth $115,000. 93.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on EMBC. BTIG Research reissued a “buy” rating and issued a $25.00 target price on shares of Embecta in a report on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. One analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $18.50.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.